+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07077057

Evaluating AI-assisted ECG Interpretation for Early Detection and Treatment of Occlusion Myocardial Infarction in Adults With Suspected Acute Coronary Syndrome

Led by Cardiocentro Ticino · Updated on 2026-05-05

500

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether an artificial intelligence AI-based ECG interpretation tool can improve the early diagnosis and treatment of occlusion myocardial infarction OMI in adults suspected of having acute coronary syndrome ACS who do not meet the traditional criteria for ST-elevation myocardial infarction STEMI. The study aims to determine if AI-assisted ECG interpretation leads to earlier coronary intervention and reduces infarct size, measured by peak high-sensitivity troponin T hsTnT levels. This trial compares AI-supported ECG interpretation with standard care to assess improvements in clinical outcomes and treatment timelines. Participants are randomly assigned to one of two groups one receives ECG interpretation assisted by a CE-marked AI tool called PMcardio, which provides real-time AI analysis to clinicians before diagnostic or treatment decisions the other group receives standard ECG interpretation without AI support, following usual care pathways. The AI tool is intended to help clinicians identify OMI earlier and potentially speed up intervention. Both groups are monitored according to their assigned care pathway. During the study, participants undergo follow-up assessments to monitor cardiovascular outcomes including death within 30 days, timing of treatment for total coronary occlusion, and peak hsTnT levels within 48 hours after randomization or intervention. Additional outcomes include major cardiovascular events, stroke, myocardial infarction, quality of life, hospital stay length, and safety over up to 10 years. The main outcome measure is a hierarchical endpoint assessed at 30 days, with various measurements taken periprocedurally and during follow-up.

CONDITIONS

Brief Title

Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here